Cargando…

In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability

Detalles Bibliográficos
Autores principales:	Casagrande, Naike, Borghese, Cinzia, Aldinucci, Donatella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719077/ https://www.ncbi.nlm.nih.gov/pubmed/34498447 http://dx.doi.org/10.3324/haematol.2021.279389

Ejemplares similares

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth
por: Casagrande, Naike, et al.
Publicado: (2019)

Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It
por: Aldinucci, Donatella, et al.
Publicado: (2019)

Current and Emerging Approaches to Study Microenvironmental Interactions and Drug Activity in Classical Hodgkin Lymphoma
por: Casagrande, Naike, et al.
Publicado: (2022)

The CCL5/CCR5 Axis in Cancer Progression
por: Aldinucci, Donatella, et al.
Publicado: (2020)

Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer
por: Aldinucci, Donatella, et al.
Publicado: (2018)

Adipose-Derived Stem Cells Primed with Paclitaxel Inhibit Ovarian Cancer Spheroid Growth and Overcome Paclitaxel Resistance
por: Borghese, Cinzia, et al.
Publicado: (2020)

Analogs of a Natural Peptaibol Exert Anticancer Activity in Both Cisplatin- and Doxorubicin-Resistant Cells and in Multicellular Tumor Spheroids
por: Casagrande, Naike, et al.
Publicado: (2021)

In Ovarian Cancer Multicellular Spheroids, Platelet Releasate Promotes Growth, Expansion of ALDH+ and CD133+ Cancer Stem Cells, and Protection against the Cytotoxic Effects of Cisplatin, Carboplatin and Paclitaxel
por: Casagrande, Naike, et al.
Publicado: (2021)

FGF2 engineered SPIONs attenuate tumor stroma and potentiate the effect of chemotherapy in 3D heterospheroidal model of pancreatic tumor
por: Mardhian, Deby Fajar, et al.
Publicado: (2020)

Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells
por: Borghese, Cinzia, et al.
Publicado: (2017)

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists
por: Schlecht, Hans P, et al.
Publicado: (2008)

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
por: Lorenzen, Thore
Publicado: (2010)

Potent In Vitro and In Vivo Anticancer Activity of New Bipyridine and Bipyrimidine Gold (III) Dithiocarbamate Derivatives
por: Altaf, Muhammad, et al.
Publicado: (2019)

Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model
por: Ochoa-Callejero, Laura, et al.
Publicado: (2013)

Comment on “Fibroblasts in Nodular Sclerosing Classical Hodgkin Lymphoma Are Defined by a Specific Phenotype and Protect Tumor Cells from Brentuximab-Vedotin Induced Injury” Cancers 2019, 11, 1687
por: Aldinucci, Donatella, et al.
Publicado: (2020)

New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status
por: Altaf, Muhammad, et al.
Publicado: (2016)

The CCR5 antagonist maraviroc exerts limited neuroprotection without improving neurofunctional outcome in experimental pneumococcal meningitis
por: Le, Ngoc Dung, et al.
Publicado: (2022)

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
por: López-Huertas, María Rosa, et al.
Publicado: (2017)

A CCR5 antagonist, maraviroc, alleviates neural circuit dysfunction and behavioral disorders induced by prenatal valproate exposure
por: Ishihara, Yasuhiro, et al.
Publicado: (2022)

Fibroblast α11β1 Integrin Regulates Tensional Homeostasis in Fibroblast/A549 Carcinoma Heterospheroids
por: Lu, Ning, et al.
Publicado: (2014)

CCR5 Antagonist Maraviroc Inhibits Acute Exacerbation of Lung Inflammation Triggered by Influenza Virus in Cigarette Smoke-Exposed Mice
por: Ferrero, Maximiliano Ruben, et al.
Publicado: (2021)

In Vitro Downregulation of Matrix Metalloproteinase-9 in Rat Glial Cells by CCR5 Antagonist Maraviroc: Therapeutic Implication for HIV Brain Infection
por: Gramegna, Pasqua, et al.
Publicado: (2011)

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
por: Roche, Michael, et al.
Publicado: (2011)

Stochastic Model of In-Vivo X4 Emergence during HIV Infection: Implications for the CCR5 Inhibitor Maraviroc
por: Savkovic, Borislav, et al.
Publicado: (2012)

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
por: Giaquinto, Carlo, et al.
Publicado: (2018)

A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics
por: Karris, Maile Y., et al.
Publicado: (2016)

Long-term viability of allogenic donor stroma
por: Carpel, Emmett F, et al.
Publicado: (2020)

A Topical Microbicide Gel Formulation of CCR5 Antagonist Maraviroc Prevents HIV-1 Vaginal Transmission in Humanized RAG-hu Mice
por: Neff, C. Preston, et al.
Publicado: (2011)

Hippocampal CCR5/RANTES Elevations in a Rodent Model of Post-Traumatic Stress Disorder: Maraviroc (a CCR5 Antagonist) Increases Corticosterone Levels and Enhances Fear Memory Consolidation
por: Merino, José Joaquín, et al.
Publicado: (2020)

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis
por: Puengel, Tobias, et al.
Publicado: (2022)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Trabectedin Is Active against Two Novel, Patient-Derived Solitary Fibrous Pleural Tumor Cell Lines and Synergizes with Ponatinib
por: Ghanim, Bahil, et al.
Publicado: (2022)

Blocking the CCL5–CCR5 Axis Using Maraviroc Promotes M1 Polarization of Macrophages Cocultured with Irradiated Hepatoma Cells
por: Zhuang, Yuan, et al.
Publicado: (2021)

Dopamine Levels Induced by Substance Abuse Alter Efficacy of Maraviroc and Expression of CCR5 Conformations on Myeloid Cells: Implications for NeuroHIV
por: Matt, Stephanie M., et al.
Publicado: (2021)

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations
por: Roche, Michael, et al.
Publicado: (2013)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015)

Trabectedin for soft tissue sarcoma
Publicado: (2021)

The CCR4-NOT Complex Is Implicated in the Viability of Aneuploid Yeasts
por: Tange, Yoshie, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_5542gvboovnecjsnem7nhgqlc1